Mon, Jul 14, 2014, 5:59 AM EDT - U.S. Markets open in 3 hrs 31 mins


% | $
Quotes you view appear here for quick access.

Santarus, Inc. (SNTS) Message Board

  • hofno2003 hofno2003 Sep 28, 2012 2:43 AM Flag

    Ruconest PR: Pharming completes Phase III hereditary angioedema study

    Pharming had a PR concerning Ruconest US pivotal Phase III trial.

    To read the article please google with the term:
    "Pharming completes Phase III hereditary angioedema study"


    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Important to know: Ruconest has orphan designation by FDA and an SPA. Perhaps we get a priority review and the drug is approved within 6 months from filing the NDA. This could be - IMHO - April 2013 (if filed in November).

      SNTS estimates the revenue potential to 200 mio usd, so the value of approved Ruconest for SNTS should 200mio usd / 62 mio shares = 3 usd per share x 3 (revenue multiple) = 9 usd. Thats a double from todays share price and will be gradually realised in the future.


      Sentiment: Strong Buy

31.960.00(0.00%)Dec 31 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Kodiak Oil & Gas Corp.
NYSEFri, Jul 11, 2014 4:02 PM EDT
USG Corporation
NYSEFri, Jul 11, 2014 4:03 PM EDT